176 results about "Immunomodulating Agent" patented technology

The invention discloses an ultralow-viscosity water-in-oil vaccine adjuvant and a preparation method thereof, and the ultralow-viscosity water-in-oil vaccine adjuvant comprises the following components in percentage by weight: 73%-75% of oil for injection, 20%-23% of a compound emulsifier, 2%-7% of a stabilizer, 0.5%-1.5% of a chiral immunomodulator and 1%-2% of a temperature-responsive material, the preparation method comprises the following steps: heating oil for injection as an oil phase; adding the compound emulsifier, the stabilizer, the chiral immunomodulator and the temperature response type material into the oil phase, stirring until the materials are completely dissolved to form a uniform oil phase mixture, slowly adding the water phase into the oil phase mixture, performing high-speed shearing to form primary emulsion, homogenizing the primary emulsion, and performing freeze drying to obtain the chiral immunomodulator. And carrying out emulsion refining by adopting a micro-fluidic technology to obtain the ultralow-viscosity water-in-oil type vaccine adjuvant. The ultra-low viscosity and injection comfort are achieved, precise immunization is achieved for different pathogens, multiple immune pathways are activated at the same time, a wide and lasting protection effect is generated by training an immune mechanism, and the ultra-low viscosity and injection comfort have the intelligent drug release characteristic, excellent stability and broad-spectrum applicability.

The invention discloses an application and method of SAH-CIM hydrogel in promoting survival of retinal ganglion cells in glaucoma. The hydrogel comprises a Y-type primitive composed of three DNA chains and a siRNA connector, and the nucleotide sequences of the three DNA chains are SEQ ID NO.1-SEQ ID NO.3; the method comprises the following steps: S1, constructing a Y-type primitive: mixing three DNA chains with equal molar concentration in an annealing buffer solution, performing high-temperature denaturation at 95 DEG C, and then quickly cooling to 4 DEG C to finish annealing, so as to form a stable Y-type structure with three-way cohesive ends; s2, synthesizing a siRNA (small interfering Ribonucleic Acid) connector; and S3, mixing the Y-type element and the siRNA connector according to a molar ratio of 1: 1.5 at room temperature to react for 30 minutes, and forming a three-dimensional network structure through complementary pairing driven self-assembly, thereby finally obtaining the SAH-CIM hydrogel. The SAH-CIM hydrogel provided by the invention can be used for preventing / treating ischemia-reperfusion injury and related diseases, for example, the SAH-CIM hydrogel can be used for treating glaucoma, accurate co-delivery of a neuroprotective agent and an immunomodulator can be realized, and the SAH-CIM hydrogel has the advantages of treatment accuracy and biocompatibility.

This application relates to trans amplifying RNAs encoding immune modulating proteins, and methods of use thereof for payload expression in cells and subjects.

The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I)In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.

The present disclosure provides for a synthetic immunogenic protein for use as an immuno-modulatory agent to enhance mammalian immune reactions towards conjugated protein or peptide containing antigens that are otherwise poorly immunogenic, including but not limited to self-antigens. The chimeric immunogenic proteins of the present disclosure can be used in the treatment of many illnesses, including but not limited to cancers, infectious disease, autoimmune disease, allergies and any clinical indication involving or affected by the immune response of a mammalian host.

Compositions and methods of use for modulating APOE mediated signaling are provided. For example, immunomodulatory agents are provided that reduce APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. In another embodiment, immunomodulatory agents are provided that enhance or promote APOE expression, ligand binding, crosslinking, APOE mediated signaling, or a combination thereof. Such agents can be used to modulate an immune response in a subject in need thereof, wherein the subject has a neurodegenerative disease, such as Alzheimer's disease or cerebral amyloid angiopathy.

The application discloses an active oxygen response type bacteriostatic and repair promoting hydrogel and a preparation method and application thereof, the hydrogel is formed by disulfide bond cross-linked hydrogel in response to active oxygen free radicals in the vagina of vaginitis patients through thiol modified hyaluronic acid (HASH), and can enhance in-vivo retention by thiol and vaginal tissue interaction. Cationic surfactant such as didecyldimethylammonium chloride (DDAC) as the bacteriostatic component of the hydrogel, efficiently killing pathogenic bacteria while having good biocompatibility, and is not prone to cause bacterial drug resistance. As a natural immune regulator, beta-glucan regulates the vaginal microenvironment, promotes the polarization of macrophages into anti-inflammatory M2 type and promotes cell migration, etc., to promote the repair of the vaginal immune barrier, regulate the vaginal flora, and reduce the probability of vaginitis recurrence. The HASH hydrogel provides an efficient, convenient and highly transformative potential strategy to provide more choices for the treatment of vaginitis.

The present invention relates to a PROTAC compound which can increase the degradation effect of a protein of interest, and to a novel piperidinedione compound which can be used as an E3 enzyme ligand of the PROTAC compound. The piperazinedione derivative compound of the present invention acts on CRBN and thus may be used as a therapeutic agent (for example, an anticancer agent or an immunomodulator) for diseases associated with CRBN proteins.

The present application relates to a kind of nasal ala base subperiosteal implant retention method, belong to plastic surgery medical instrument technical field.The present application provides a kind of nasal ala base subperiosteal implant soft tissue suspension retention method and its implant and system.The method includes: implant is placed into maxillary bone subperiosteal interstice, and implant fixed wing is fixed with the soft tissue anchor point such as alar base ligament of alar elevating lip muscle using drug-loaded degradable suture and is suspended and fixed.Implant surface is provided with the microporous structure of guiding tissue ingrowth, and is provided with the drug depot recess of filling load immunomodulator temperature-sensitive hydrogel.Postoperative healing process, suture is released under the action of tension to accelerate proangiogenic factor and promote local vascularization, and temperature-sensitive hydrogel slow-release immunomodulator induces macrophage to repair type polarization, and cooperatively promotes the biological chimeric fixation of implant and soft tissue.The present application can realize the double stable retention of implant, reduces postoperative displacement risk.

The present disclosure describes pyridinone-containing inhibitors of PD-L1, pharmaceutical compositions containing these compounds, chemical processes for preparing these compounds, and their use in the treatment of infectious diseases and cancer. Formula (I): [Formula 1] TIFF2022535879000052.tif30170

Provided herein are uses of T cells, e.g., chimeric antigen receptor (CAR) T cells, for treating a tumor or a cancer (such as B cell related cancer, e.g., multiple myeloma) wherein the subject being treated has previously received a topoisomerase inhibitor, a proteasome inhibitor, an anti-CD38 agent, an immunomodulatory agent, or an anti-SLAMF agent therapy.

In some aspects, disclosed herein are compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of Staphylococcus aureus. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders.

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

The present invention refers to the field of peptides, particularly with antimicrobial agent activity. Particularly, the present invention refers to peptides comprising the amino acid sequences as defined in the document, useful for treating and / or preventing an infection, preferably for treating and / or preventing animal mastitis, and / or as a preservative and / or as an immunomodulator. The present invention also refers to a set of peptides, to a composition, to uses of at least one peptide or the set of peptides, to a method for treating and / or preventing an infection and a kit.

Embodiments of the invention relate to embolic compositions having immunomodulating components therein and methods for using the embolic compositions to treat cancer. The embolic compositions include a hydrogel embolic with the immunomodulator(s) therein.

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

This invention relates to the field of plant extract application technology, particularly to banana fruit extract and its applications. This invention reveals that banana fruit extract exhibits excellent performance in relieving inflammation, anti-oxidation, scavenging free radicals, delaying cell aging, inhibiting viruses and bacteria (inactivating HPV, Staphylococcus aureus, Candida albicans, Escherichia coli, and Propionibacterium acnes), reducing infection, promoting cell regeneration and repair, promoting collagen synthesis, enhancing elasticity and firmness, and acting as a plant-derived immunomodulator. Furthermore, it serves as a natural, intelligent transdermal carrier. Safe and non-irritating, this extraction method has shown excellent application value in high-value plants such as saffron, rose, Dendrobium officinale, ginseng, and Ganoderma lucidum. It provides a comprehensive solution for skin from defense to regeneration, offering a regulatory-compliant natural solution for functional skincare.

The invention discloses a biphenyl compound as shown in a formula (I), and a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound as an active ingredient. The compound is a novel small molecule immunomodulator having an excellent oral absorbable characteristic, and can be used for treating and / or preventing various diseases related to immunity.

This invention discloses a preparation process for a homogeneous immunomodulatory polysaccharide from *Gynostemma pentaphyllum* and its application in the preparation of anti-melanoma drugs and immunomodulators, relating to the field of pharmaceutical manufacturing technology. The preparation process includes four steps: compound enzyme-ultrasound synergistic extraction, fractional alcohol precipitation to remove proteins, DEAE-52 ion exchange column chromatography, and Sephacryl S-400 gel permeation chromatography purification. The resulting homogeneous polysaccharide (GOP-3) has a weight-average molecular weight of 12±1 kDa and is composed of mannose, glucose, and galactose in a specific ratio. The GOP-3 of this invention has a weight-average molecular weight (Mw) of 12.8 kDa, a dispersion (Mw / Mn) < 1.2, a uronic acid content of 23.5%, a well-defined structure, and is suitable for drug application. Furthermore, GOP-3 can significantly promote the secretion of IL-12 by dendritic cells and induce the differentiation of naive T cells into Th1 cells. Simultaneously, compared with a full-dose PD-1 monoclonal antibody, the combination of GOP-3 and a half-dose monoclonal antibody not only reduces the risk of immune-mediated pneumonia caused by antibody drugs but also increases the tumor inhibition rate by more than 40%.

The present invention provides methods, devices and kits relating to treating lower tract urothelial carcinomas with an antimetabolite (such as gemcitabine). In some aspects the methods, devices and kits relate to treating lower tract urothelial carcinomas with an antimetabolite (such as gemcitabine) and an immunomodulatory agent.

Disclosed herein are methods of using immunomodulatory sterols as vaccine adjuvants. Accordingly, certain embodiments relates to pharmaceutical compositions containing at least one antigen and at least one immunomodulatory sterol; and, methods of inducing an immunomodulatory response in a patient by administering an immunomodulatory-effective amount of at least one immunomodulatory sterol.

This invention discloses a type of click-type covalent drug, its regionally selective delivery system, and its applications. The invention comprises two parts: a click-type covalent drug and a tumor regionally selective delivery system. The click-type covalent drug consists of three parts: an azacyclic alkyne (DBCO), a small molecule drug, and a linker, having the structure of Formula 1. Optionally, the small molecule drug is a membrane protein inhibitor, an immunomodulator, or a chemotherapeutic drug. The click-type covalent drug reacts with azide-labeled target cells via a click reaction, forming a covalent bond that binds to the cell membrane, increasing the local drug concentration and prolonging the drug retention time, thereby enhancing selective inhibition of the target cells. The regionally selective delivery system is co-assembled from an amphiphilic block polymer and the click-type covalent drug for regionally selective delivery. This invention achieves covalent binding to azide-labeled tumor cells through the click-type covalent drug, while having no effect on unlabeled normal cells, reducing toxic side effects on normal tissues.

The invention discloses an application of 8-methyl quercetin in preparation of a TLR7 (toll-like receptor 7) immunomodulator. According to the invention, it is found that 8-methyl quercetin can be used as a ligand of TLR7, and the 8-methyl quercetin has strong binding and interaction with swine TLR7 protein. Therefore, the 8-methyl quercetin can be used as an immunomodulator or a lead compound acting on the TLR7. As the TLR7 protein is conservative in evolution, the application of the 8-methyl quercetin is not limited to pigs, and the 8-methyl quercetin can also be applied to other species.

The application discloses an immunomodulator, and particularly relates to a kind of compounds for inhibiting IL-17A and purposes of the compounds as immunomodulator in preparing medicine.The application discloses purposes of the compound shown in formula I or formula II, or stereoisomer thereof in preparing IL-17A inhibiting medicine, and provides a new choice for screening and / or preparing medicine for the disease related to IL-17A activity in clinic. Formula I Formula II

The invention discloses a biphenyl compound as shown in a formula (I), and a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound as an active ingredient. The compound is a novel small molecule immunomodulator having an excellent oral absorbable characteristic, and can be used for treating and / or preventing various diseases related to immunity.

This disclosure relates to extracellular vesicles (EVs), such as exosomes, comprising a payload (e.g., an antigen, adjuvant, and / or immunomodulator) and / or a targeting portion. Methods for generating EVs (e.g., exosomes) and methods for using EVs (e.g., exosomes) to treat and / or prevent diseases or conditions, such as cancer, graft-versus-host disease (GvHD), autoimmune diseases, infectious diseases, or fibrotic diseases, are also provided herein.

The application discloses a polymer microneedle patch co-loaded with self-antigen peptides and immunomodulators and a preparation method thereof, and studies the ability of the polymer microneedle patch to reverse immune dysfunction of rheumatoid arthritis (RA). The preparation method is as follows: a biocompatible polymer matrix material and a self-antigen are dissolved in pure water, and then an immunomodulator is added to obtain a suspension by stirring. The suspension is added to a mold to form needle tips, a backing layer solution is poured after drying, and finally the microneedle patch is demolded. Animal experiments show that the microneedle has sufficient mechanical strength to deliver drugs transdermally, effectively induces tolerogenic dendritic cells at the drug delivery site, further activates the differentiation of regulatory T cells (Treg), significantly up-regulates anti-inflammatory cytokines, down-regulates pro-inflammatory cells, antibodies and cytokines, effectively restores the immune balance of rheumatoid arthritis, and finally almost completely eliminates the symptoms and inflammatory infiltrates of rheumatoid arthritis. The microneedle preparation method is simple and rapid, and has a good clinical transformation prospect.

The invention discloses a space-time responsive multifunctional 3D printing bone repair scaffold as well as a preparation method and application thereof. PDGF-BB is loaded on a quick-release carrier, MgP is loaded on a slow-release carrier, and the multifunctional 3D printing bone repair scaffold with MgP loaded on the inner layer and PDGF-BB loaded on the outer layer is prepared through 3D printing. Wherein the PDGF-BB is used as an immunomodulator, the MgP is used as a regeneration inducer, and after the carrier is implanted into a body, according to different carrier degradation rates, the PDGF-BB is degraded and released in a space-time responsive manner to realize early immunoregulation and endothelial cell recruitment, and then magnesium ions and phosphate ions are degraded and released to synergistically promote vascularization and osteogenesis in middle and later periods with the PDGF-BB. In-vitro and in-vivo experiments prove that the 3D printing bone repair scaffold provided by the invention has immunoregulation, angiogenesis promotion and osteogenesis properties, can be used for repairing inflammatory bone injury, and is particularly suitable for repairing inflammatory bone injury caused by diabetes.